Acurx Pharmaceuticals Inc
NASDAQ:ACXP
Intrinsic Value
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ACXP.
Acurx Pharmaceuticals Inc's market capitalization is 30.7m USD.
ACXP stock price is 2.12 USD.
ACXP.
ACXP. Open DCF Valuation
ACXP. Open Relative Valuation
ACXP has upside potential of 482% compared to the average analyst price target.
Open Wall St Estimates
ACXP has negative Free Cash Flow for the last twelve months.
ACXP has negative Operating Income for the last twelve months.
ACXP has negative Net Income for the last twelve months.
ACXP's ROE (Return on Equity) has significantly decreased in the last 3 years from -194% to -243%, and is approaching profitability.
ACXP's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -1 366% to -6 189%, and is approaching profitability.
ACXP's ROE (Return on Equity) for the past 12 months is negative and is equal to -243%.
ACXP's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -6 189%.
ACXP's short-term assets (8m USD) exceed its short-term liabilties (3m USD).
ACXP's long-term assets (8m USD) exceed its long-term liabilties (3m USD).
ACXP has negative three-year average ROE (Return on Equity): -132%. The company is not efficient at transforming stockholders' equity into net income.
ACXP has negative three-year average ROIC (Return on Invested Capital): -4 636%. The company is not efficient at using invested capital to generate operating income.
ACXP's D/E (Debt to Equity) is very low and is equal to 0.
ACXP's Altman Z-Score is very low and is equal to -5.41.
Fundamental Analysis
Acurx Pharmaceuticals Inc
Balance Sheet Decomposition
Acurx Pharmaceuticals Inc
| Current Assets | 7.7m |
| Cash & Short-Term Investments | 7.5m |
| Receivables | 129.2k |
| Other Current Assets | 105.8k |
| Current Liabilities | 3m |
| Accounts Payable | 3.8k |
| Accrued Liabilities | 3m |
Earnings Waterfall
Acurx Pharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-14.6m
USD
|
|
Operating Income
|
-14.6m
USD
|
|
Other Expenses
|
0
USD
|
|
Net Income
|
-14.6m
USD
|
Free Cash Flow Analysis
Acurx Pharmaceuticals Inc
ACXP Profitability Score
Profitability Due Diligence
Acurx Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Acurx Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ACXP Solvency Score
Solvency Due Diligence
Acurx Pharmaceuticals Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Acurx Pharmaceuticals Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ACXP Price Targets Summary
Acurx Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
ACXP
is 12.33 USD
with a low forecast of 10.1 USD and a high forecast of 14.7 USD.
Ownership
ACXP Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ACXP Price
Acurx Pharmaceuticals Inc
| Average Annual Return | -15.43% |
| Standard Deviation of Annual Returns | 13.07% |
| Max Drawdown | -84% |
| Market Capitalization | 30.7m USD |
| Shares Outstanding | 15 757 100 |
| Percentage of Shares Shorted | 2.53% |
Company Profile
Acurx Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Staten Island, New York and currently employs 3 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in developing a class of antibiotics for infections caused by bacteria listed as pathogens by the World Health Organization (WHO), the United States Centers for Disease Control and Prevention, and the United States Food and Drug Administration (FDA). The firm develops antibiotic candidates that block the deoxyribonucleic acid (DNA) polymerase IIIC enzyme (Pol IIIC). Pol IIIC is the primary catalyst for DNA replication in Gram-positive bacterial cells. Its research and development pipeline include clinical-stage and early stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile, Enterococcus, including vancomycin-resistant strains (VRE), Staphylococcus, including methicillin-resistant strains (MRSA), and Streptococcus, including antibiotic-resistant strains.
You don't have any saved screeners yet
